Atlas Trials

Erdafitinib Monotherapy or in Combination With Cetrelimab in Muscle-invasive Bladder Cancer Patients With Fibroblast Growth Factor Receptor (FGFR ) Gene Alterations

Clinical trial NCT06511648 · RECRUITING

Trial details

NCT number
NCT06511648
Sponsor
Spanish Oncology Genito-Urinary Group
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Muscle-invasive Bladder Cancer
Start date
2023-03-07
Primary completion
2026-07-01
Enrollment
90

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.